In brief
- Ibogaine, an alkaloid from the African iboga shrub, is being explored as a tool to assist in overcoming opioid dependency; it appears to attenuate withdrawal symptoms and cravings.
- Most of what we know comes from observational studies and early-phase research; clinical trials are currently underway in Spain, the United States, and other countries.
- Its most delicate aspect is the heart (QT interval prolongation and arrhythmias). As of today, it is not an authorized medication by the EMA or the AEMPS, a fact to keep in mind when seeking information.
Ibogaine generates interest due to an unusual possibility: helping to interrupt opioid dependency, sometimes with a single dose. It is worth examining it calmly, distinguishing what the data suggests from what has not yet been proven, and understanding its risks well to make an informed decision.
What is ibogaine?
It is an indole alkaloid present in the root of Tabernanthe iboga, a West African shrub used since ancient times in the Bwiti rites of Gabon. In the mid-20th century, it was observed that certain doses seemed to reduce the desire to consume opioids, and since then it has been administered primarily in private clinics and unregulated settings in countries like Mexico or Costa Rica for “detoxification” purposes. In the body, it is transformed into noribogaine, a longer-lasting metabolite produced by the hepatic enzyme CYP2D6, whose activity varies greatly from person to person. This is an important detail for understanding why response and safety are not the same for everyone.
What the evidence says about opioids
Many accounts and case series describe that, after a dose, withdrawal symptoms and craving decrease for days or weeks. Several observational and open-label studies point in the same direction, although they are small, lack a comparison group, and carry biases that should be kept in mind. A Dutch open-label study published in the journal Addiction (Knuijver et al., 2022), with 14 people undergoing opioid treatment, found that 11 did not return to morphine use in the following 24 hours, although with notable adverse effects. It is an interesting indication, but not yet proof of efficacy.
More rigorous research is still ongoing. In Spain, a phase II trial is being developed at the Hospital Sant Joan de Reus with patients from a methadone program, and in the United States, controlled trials are underway, some linked to Stanford University. In 2024, Nature Medicine published a study on thirty veterans with brain injuries that combined ibogaine with magnesium; although its focus was trauma (post-traumatic stress, depression) and not opioids, it illustrates the renewed scientific interest and the utility of well-designed safety protocols. The honest reading is that there are promising signals based on evidence that is still preliminary.
The heart, the central issue
The aspect that requires the most attention is not efficacy, but the heart. Ibogaine blocks a cardiac potassium channel (hERG) and prolongs the QT interval on the electrocardiogram, which can promote serious arrhythmias. Systematic reviews have documented deaths associated with its use, mostly in unsupervised contexts and related to pre-existing heart disease, high doses, or the simultaneous use of other depressants such as opioids or benzodiazepines. The Knuijver study itself observed relevant QT prolongations that in some cases persisted for more than 24 hours. That is why current research relies on cardiac screening, continuous electrocardiogram monitoring, electrolyte control, and protective strategies such as magnesium: these are precisely the conditions that make the difference between a supervised context and one that is not.
Harm reduction
Anyone considering ibogaine deserves clear information to take care of themselves. As a reference, it is not currently authorized as a medication by the European Medicines Agency (EMA) or the Spanish Agency for Medicines and Health Products (AEMPS), so its use remains outside of regulated clinical practice. From there, some keys to reducing risks: the most delicate area is the heart, so a prior heart evaluation, an electrocardiogram, and electrolyte control provide a very valuable safety margin. It is advisable to avoid combining it with opioids, benzodiazepines, or other drugs that prolong the QT interval, as that mixture concentrates a large part of the risk. The option with the most guarantees is to participate in an authorized clinical trial, with medical and cardiac supervision. And if at any point you want to address dependency through paths with extensive evidence, there are methadone, buprenorphine, and naltrexone; in the event of an opioid overdose, the response is naloxone and calling 112.
Sources
- Knuijver, T. et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals. Addiction, 2022.
- Cherian, K. N. et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, January 2024.
- National Institute on Drug Abuse (NIDA). Psychedelic and Dissociative Drugs. NIDA, 2024.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
